BPG is committed to discovery and dissemination of knowledge
Case Report
©The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Feb 6, 2026; 14(4): 117573
Published online Feb 6, 2026. doi: 10.12998/wjcc.v14.i4.117573
Mixed hepatocellular-cholestatic liver injury from cefepime: A case report
Reicelle Garcia, Kevan English
Reicelle Garcia, Department of Internal Medicine, Creighton University Medical Center - Bergan Mercy, Omaha, NE 68124, United States
Kevan English, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198, United States
Co-first authors: Reicelle Garcia and Kevan English.
Author contributions: Garcia R and English K wrote the original draft, contributed to conceptualization, writing, reviewing, and editing; the authors read and approved the final version of the manuscript.
Informed consent statement: Written informed consent was obtained from the patient regarding the publication of this article and the associated image.
Conflict-of-interest statement: All authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Corresponding author: Kevan English, MD, Department of Internal Medicine, University of Nebraska Medical Center, 42nd and Emile Street, Omaha, NE 68198, United States. keenglish@unmc.edu
Received: December 11, 2025
Revised: December 29, 2025
Accepted: January 23, 2026
Published online: February 6, 2026
Processing time: 57 Days and 2.7 Hours
Core Tip

Core Tip: Cefepime is a fourth-generation cephalosporin commonly used to treat various bacterial infections. It is safe and generally well-tolerated. While frequently associated with adverse effects such as neurotoxicity and nephrotoxicity, cases of hepatotoxicity are rare. Prompt cessation of the medication is the primary approach in management.

Write to the Help Desk